Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Panelists discuss the primary access challenges in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) treatment, including financial barriers and health care system limitations, and how ...

STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell ...

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

Data from Two Key Studies Highlight CrossReactivity and BroadSpectrum Immunity of GEO-CM04S1 and GeoVax Multi-Antigen Vaccine ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug ...

HemOnc Today hosted its fourth Disruptive Innovators Awards ceremony, crowning nine new winners at ASCO Annual Meeting. Co-hosted by Shikha Jain, MD, FACP, founder of Women in Medicine, and Ed S. Kim, ...

This National Cancer Survivor Month, St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., is proud to launch its June campaign, "Their Next Chapter ...

BeOne Medicines Ltd. (NASDAQ:ONC) has unveiled new data from the pivotal Phase 3 SEQUOIA trial at the 2025 ASCO Annual ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...